Bristol-Myers Squibb Co
CELG_r0.025
-0.014-37.09%
Close 05/19, 16:00（ET）Quotes delayed by 15 min
--Market Cap
--P/E TTM
More Details of Bristol-Myers Squibb Co Company
Bristol-Myers Squibb Company is a global biopharmaceutical company. It is engaged in the discovery, development and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its platforms comprise chemically synthesized or small molecule drugs, including protein degraders; drugs produced from biological processes, called biologics; ADCs, CAR-T cell therapies, and radiopharmaceutical therapeutics. Small molecule drugs are typically administered orally in the form of a tablet or capsule, although other drug delivery mechanisms are also used. Biologics are typically administered through injections or by intravenous infusion. CAR-T cell therapies are administered by intravenous infusion. Its growth portfolio includes Opdivo, Opdivo Qvantig, Orencia, Yervoy, Reblozyl, Opdualag, and others. Its legacy portfolio includes Eliquis, Revlimid, Pomalyst/Imnovid, Sprycel and Abraxane.
Company Info
Company codeCELG_r
Company nameBristol-Myers Squibb Co
IPO dateMar 17, 1980
Founded at1933
CEODr. Christopher S. (Chris) Boerner, Ph.D.
Number of employees- -
Security type- -
Fiscal year-end- -
AddressRoute 206 And Province Line Road
CityPRINCETON
Stock exchange- -
CountryUnited States of America
Postal code08543
Phone16092524621
Websitehttps://www.bms.com
Company codeCELG_r
IPO dateMar 17, 1980
Founded at1933
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Michael R. (Mike) Mcmullen
Mr. Michael R. (Mike) Mcmullen
Independent Director
Independent Director
--
--
Mr. Benjamin Hickey
Mr. Benjamin Hickey
President - RayzeBio Organization, Member of the Leadership Team
President - RayzeBio Organization, Member of the Leadership Team
--
--
Dr. Julia A. Haller, M.D.
Dr. Julia A. Haller, M.D.
Independent Director
Independent Director
--
--
Ms. Lynelle Hoch
Ms. Lynelle Hoch
President, Cell Therapy Organization, Member of the Leadership Team
President, Cell Therapy Organization, Member of the Leadership Team
--
--
Ms. Phyllis R. Yale
Ms. Phyllis R. Yale
Independent Director
Independent Director
--
--
Mr. Greg Scott Meyers
Mr. Greg Scott Meyers
Executive Vice President, Chief Digital and Technology Officer, Member of the Leadership Team
Executive Vice President, Chief Digital and Technology Officer, Member of the Leadership Team
--
--
Ms. Amanda Poole
Ms. Amanda Poole
Executive Vice President, Chief People Officer, Member of the Leadership Team
Executive Vice President, Chief People Officer, Member of the Leadership Team
--
--
Dr. Manuel Hidalgo Medina, M.D., Ph.D.
Dr. Manuel Hidalgo Medina, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Robert Plenge, M.D., Ph.D.
Mr. Robert Plenge, M.D., Ph.D.
Executive Vice President, Chief Research Officer, Head of Research, Member of the Leadership Team
Executive Vice President, Chief Research Officer, Head of Research, Member of the Leadership Team
--
--
Mr. Samit Hirawat, M.D.
Mr. Samit Hirawat, M.D.
Executive Vice President, Chief Medical Officer, Head of Development, Member of the Leadership Team
Executive Vice President, Chief Medical Officer, Head of Development, Member of the Leadership Team
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Michael R. (Mike) Mcmullen
Mr. Michael R. (Mike) Mcmullen
Independent Director
Independent Director
--
--
Mr. Benjamin Hickey
Mr. Benjamin Hickey
President - RayzeBio Organization, Member of the Leadership Team
President - RayzeBio Organization, Member of the Leadership Team
--
--
Dr. Julia A. Haller, M.D.
Dr. Julia A. Haller, M.D.
Independent Director
Independent Director
--
--
Ms. Lynelle Hoch
Ms. Lynelle Hoch
President, Cell Therapy Organization, Member of the Leadership Team
President, Cell Therapy Organization, Member of the Leadership Team
--
--
Ms. Phyllis R. Yale
Ms. Phyllis R. Yale
Independent Director
Independent Director
--
--
Mr. Greg Scott Meyers
Mr. Greg Scott Meyers
Executive Vice President, Chief Digital and Technology Officer, Member of the Leadership Team
Executive Vice President, Chief Digital and Technology Officer, Member of the Leadership Team
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholder
Update time: Sat, May 17
Update time: Sat, May 17
Shareholder Statistics
Type
Shareholder Statistics
Shareholder
Proportion
Other
100.00%
Shareholder Statistics
Shareholder
Proportion
Other
100.00%
Type
Shareholder
Proportion
Other
100.00%
Institutional Shareholding
Update time: Mon, Mar 3
Update time: Mon, Mar 3
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q1
32
935.03K
0.00%
+254.91K
2024Q4
32
943.43K
0.00%
+289.58K
2024Q3
31
601.53K
0.00%
-30.97K
2024Q2
30
511.50K
0.00%
+7.21K
2024Q1
32
397.74K
0.00%
-298.70K
2023Q4
30
495.62K
0.00%
-151.97K
2023Q3
30
535.93K
0.00%
-247.50K
2023Q2
31
542.98K
0.00%
-138.59K
2023Q1
34
441.11K
0.00%
-360.09K
2022Q4
39
517.53K
0.00%
-445.11K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
International Assets Investment Management, LLC
175.00
0%
+175.00
--
Jun 30, 2024
Transcend Capital Advisors, LLC
117.78K
0%
--
--
Dec 31, 2024
Davenport Asset Management
83.97K
0%
--
--
Dec 31, 2024
Maven Investment Partners US Ltd.
67.86K
0%
+67.86K
--
Dec 31, 2024
BofA Global Research (US)
51.64K
0%
--
--
Dec 31, 2024
Purkiss Capital Advisors LLC
26.45K
0%
+26.45K
--
Dec 31, 2024
Two Sigma Investments, LP
26.14K
0%
+10.37K
+65.77%
Dec 31, 2024
MainStreet Advisors
20.00K
0%
--
--
Dec 31, 2024
Watts Gwilliam & Co LLC
20.00K
0%
--
--
Dec 31, 2024
Private Advisor Group LLC
15.00K
0%
--
--
Dec 31, 2024
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
